ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countriesDublin-based subsidiary to support ImmunityBio’s distribution and ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...

Transgender women athletes do not have an inherent advantage over cisgender competitors, according to a new study. That’s ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...

Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial ...

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

Protara Therapeutics has announced updated interim results from its ongoing Phase II open-label ADVANCED-2 trial assessing ...

ImmunityBio inks partnership with Biopharma & Cigalah to introduce Anktiva in Saudi Arabia for bladder and lung cancer patients: Culver City, California Monday, February 23, 2026, ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.